Clinical Trial ResultsThe benefits observed in the Phase 1/2a study remain after three years post-dosing, supporting the potential of OpRegen as a one-time therapy that can alter the course of this progressive disease.
Financial StabilityManagement believes the current cash position provides runway into 1Q27, indicating financial stability for the company.
Strategic PartnershipsWith Roche’s backing, Lineage remains well ahead in clinical progress, building momentum in the field.